Investment Rating - The investment rating for the company is "Buy" [1][7] Core Views - The company reported a significant improvement in its combined operating ratio (COR) and continued high growth in new business value (NBV) [2][3] - The company achieved a revenue of 324.01 billion yuan in H1 2025, representing a year-on-year increase of 10.8%, and a net profit attributable to shareholders of 26.53 billion yuan, up 16.9% year-on-year [2] - The company plans to distribute an interim cash dividend of 0.075 yuan per share, an increase of 19.0% year-on-year [2] Summary by Sections Premium Growth and Underwriting Improvement - In H1 2025, the company achieved original premium income of 323.28 billion yuan, a year-on-year increase of 3.6%, with insurance service income of 249.04 billion yuan, up 5.6% [3] - The underwriting profit reached 11.70 billion yuan, a year-on-year increase of 53.5%, with a COR of 95.3%, improving by 1.5 percentage points year-on-year [3] - The combined loss ratio increased by 1.6 percentage points to 72.3%, while the combined expense ratio improved by 3.1 percentage points to 23.0% [3] Life and Health Insurance NBV Growth - The NBV for life insurance increased by 71.1% year-on-year to 4.978 billion yuan, with the bank insurance channel contributing significantly with a 108% increase [4] - The NBV for health insurance grew by 51% year-on-year to 3.837 billion yuan, driven by improved payment structures and reduced channel commissions [4] - The life insurance service income was 14.018 billion yuan, up 32.5% year-on-year, while original premium income increased by 14.5% [4] Investment Income and Asset Allocation - As of mid-2025, the company's investment assets reached 1,760.67 billion yuan, a year-on-year increase of 7.24% [5] - Total investment income for H1 2025 was 41.478 billion yuan, up 42.7% year-on-year, with net investment income of 30.324 billion yuan, an increase of 13.2% [5] - The annualized total investment return rate was 5.1%, up 1.0 percentage points year-on-year [5] Profit Forecast and Valuation - The company maintains its profit forecast, expecting revenues of 659.5 billion yuan, 712.6 billion yuan, and 736.8 billion yuan for 2025-2027 [6] - The expected net profit attributable to shareholders for the same period is 45.5 billion yuan, 49.1 billion yuan, and 52.9 billion yuan respectively [6] - The projected earnings per share (EPS) for 2025-2027 are 1.03 yuan, 1.11 yuan, and 1.20 yuan [6]
中国人保(601319):COR显著改善,NBV延续高增